Reference health
<p>Ruthenium Complexes as Anticancer Agents: A Brief History and Perspectives</p>
146/146 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
4 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 146 checked references that resolve
resolves10.1002/anie.201208414
Bioactive Luminescent Transition‐Metal Complexes for Biomedical Applications
resolves10.3390/molecules200917244
Editorial of Special Issue Ruthenium Complex: The Expanding Chemistry of the Ruthenium Complexes
resolves10.1021/ja058540p
High Molar Extinction Coefficient Heteroleptic Ruthenium Complexes for Thin Film Dye-Sensitized Solar Cells
resolves10.1149/1.2220996
Ruthenium Dioxide as Cathode Material for Hydrogen Evolution in Hydroxide and Chlorate Solutions
resolves10.1021/cr9002424
Ruthenium-Based Heterocyclic Carbene-Coordinated Olefin Metathesis Catalysts
resolves10.1038/nprot.2014.060
Synthesis, labeling and bioanalytical applications of a tris(2,2′-bipyridyl)ruthenium(II)-based electrochemiluminescence probe
resolves10.1039/c0an01003k
A ruthenium(ii) complex based turn-on electrochemiluminescence probe for the detection of nitric oxide
resolves10.1039/c3cc48916g
Dinuclear ruthenium(ii) polypyridyl complexes as single and two-photon luminescence cellular imaging probes
resolves10.1021/ja3100287
Detection of α-Synuclein Amyloidogenic Aggregates <i>in Vitro</i> and in Cells using Light-Switching Dipyridophenazine Ruthenium(II) Complexes
resolves10.1039/C4MT00069B
Transition metal complexes with bioactive ligands: mechanisms for selective ligand release and applications for drug delivery
resolves10.1039/c3dt32214a
Ruthenium complexes in different oxidation states: synthesis, crystal structure, spectra and redox properties
resolves10.1007/s00706-015-1484-x
On the chloride lability in electron-rich second-generation ruthenium benzylidene complexes
resolves10.1016/j.drup.2006.05.002
DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity
resolves10.1136/jcp.36.5.539
Transferrin receptors in human tissues: their distribution and possible clinical relevance.
resolves10.1071/CH12275
Sixty Years Young: The Diverse Biological Activities of Metal Polypyridyl Complexes Pioneered by Francis P. Dwyer
resolves10.1021/acs.bioconjchem.5b00093
Water-Soluble Phosphorescent Ruthenium Complex with a Fluorescent Coumarin Unit for Ratiometric Sensing of Oxygen Levels in Living Cells
resolves10.1016/j.biochi.2010.01.003
Interaction of [Ru(bpy)2(dppz)]2+ with human telomeric DNA: Preferential binding to G-quadruplexes over i-motif
resolves10.1021/bi00038a034
Correlation between Cytotoxicity and DNA Binding of Polypyridyl Ruthenium Complexes
resolves10.1021/ac201129d
Dual-Color Fluorescence and Homogeneous Immunoassay for the Determination of Human Enterovirus 71
resolves10.1039/C3SC52166D
Dinuclear ruthenium(
<scp>ii</scp>
) antimicrobial agents that selectively target polysomes in vivo
resolves10.1016/j.bmc.2009.05.071
Ruthenium complexes endowed with potent anti-Trypanosoma cruzi activity: Synthesis, biological characterization and structure–activity relationships
resolves10.1007/s00775-013-1024-2
Metal–drug synergy: new ruthenium(II) complexes of ketoconazole are highly active against Leishmania major and Trypanosoma cruzi and nontoxic to human or murine normal cells
resolves10.1039/c2cs15299a
Ruthenium(ii) polypyridyl complexes and DNA—from structural probes to cellular imaging and therapeutics
resolves10.3390/molecules190811933
Ruthenium Polypyridine Complexes Combined with Oligonucleotides for Bioanalysis: A Review
resolves10.1038/sj.bjp.0705825
Vasoactive properties of CORM‐3, a novel water‐soluble carbon monoxide‐releasing molecule
resolves10.1073/pnas.61.2.748
The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase.
resolves10.1161/01.RES.0000084381.86567.08
Cardioprotective Actions by a Water-Soluble Carbon Monoxide–Releasing Molecule
resolves10.1016/j.ejmech.2013.12.041
Syntheses and evaluation of drug-like properties of CO-releasing molecules containing ruthenium and group 6 metal
resolves10.1021/acsbiomaterials.5b00230
Macromolecular and Inorganic Nanomaterials Scaffolds for Carbon Monoxide Delivery: Recent Developments and Future Trends
resolves10.3390/molecules19045028
RutheniumII Complexes bearing Fused Polycyclic Ligands: From Fundamental Aspects to Potential Applications
resolves10.3390/inorganics2010096
Syntheses of Macromolecular Ruthenium Compounds: A New Approach for the Search of Anticancer Drugs
resolves10.2174/0929867054637626
Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches
resolves10.1200/JCO.1986.4.10.1506
Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck.
resolves10.1002/ejic.200900054
Platinum Anticancer Coordination Compounds: Study of DNA Binding Inspires New Drug Design
resolves10.1016/j.toxlet.2015.06.012
An integrated view of cisplatin-induced nephrotoxicity and ototoxicity
resolves10.1158/1078-0432.CCR-03-0746
A Phase I and Pharmacological Study with Imidazolium-<b>
<i>trans-</i>
</b>DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent
resolves10.1002/cbdv.200890195
KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
resolves10.1039/C3SC53243G
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
resolves10.1021/acs.inorgchem.7b00072
Synthesis and Photobiological Activity of Ru(II) Dyads Derived from Pyrrole-2-carboxylate Thionoesters
resolves10.1021/acs.chemrev.8b00211
Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433
resolves10.1016/S0959-8049(01)00389-6
Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A
resolves10.1016/S0003-9861(02)00218-7
The anti-metastatic agent imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway
resolves10.1007/s00432-004-0617-0
Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells
resolves10.1200/jco.2012.30.15_suppl.3033
NKP-1339: Maximum tolerated dose defined for first-in-human GRP78 targeted agent.
resolves10.1016/S0010-8545(97)00024-6
Recent advances in the chemistry of arene complexes of ruthenium(0) and ruthenium(II)
resolves10.1002/ejic.200600723
Classical and Non‐Classical Ruthenium‐Based Anticancer Drugs: Towards Targeted Chemotherapy
resolves10.1016/j.jorganchem.2010.11.009
Organometallic ruthenium-based antitumor compounds with novel modes of action
resolves10.2533/chimia.2007.698
Systematic Design of a Targeted Organometallic Antitumour Drug in Pre-clinical Development
resolves10.1039/b508531b
Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes
resolves10.1021/jm301376a
Structure–Activity Relationships of Targeted Ru<sup>II</sup>(η<sup>6</sup>-<i>p</i>-Cymene) Anticancer Complexes with Flavonol-Derived Ligands
resolves10.1007/s00775-014-1120-y
Anticancer activity of structurally related ruthenium(II) cyclopentadienyl complexes
resolves10.1021/jm500458c
Arene–Ruthenium(II) Acylpyrazolonato Complexes: Apoptosis-Promoting Effects on Human Cancer Cells
resolves10.1021/jm500455p
Discovery and Investigation of Anticancer Ruthenium–Arene Schiff-Base Complexes via Water-Promoted Combinatorial Three-Component Assembly
resolves10.1021/acs.jmedchem.5b01194
Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure–Activity Relationship Study
resolves10.1021/om500317b
Ruthenium(II)–Arene RAPTA Type Complexes Containing Curcumin and Bisdemethoxycurcumin Display Potent and Selective Anticancer Activity
resolves10.1039/C8MT00369F
Comparative antitumor studies of organoruthenium complexes with 8-hydroxyquinolines on 2D and 3D cell models of bone, lung and breast cancer
resolves10.1016/j.jinorgbio.2018.05.009
Synthesis and biological characterization of organoruthenium complexes with 8-hydroxyquinolines
resolves10.1021/jm501095r
Targeting Nucleus DNA with a Cyclometalated Dipyridophenazineruthenium(II) Complex
resolves10.1002/chem.201502154
Cyclometalated Ruthenium(II) Anthraquinone Complexes Exhibit Strong Anticancer Activity in Hypoxic Tumor Cells
resolves10.1039/c3nj00542a
Studies of ruthenium(ii)-2,2′-bisimidazole complexes on binding to G-quadruplex DNA and inducing apoptosis in HeLa cells
resolves10.1039/C4RA07102F
The studies on bioactivity in vitro of ruthenium(
<scp>ii</scp>
) polypyridyl complexes towards human lung carcinoma A549 cells
resolves10.1021/acs.jmedchem.5b00444
Water-Soluble Ruthenium(II) Complexes with Chiral 4-(2,3-Dihydroxypropyl)-formamide Oxoaporphine (FOA): In Vitro and in Vivo Anticancer Activity by Stabilization of G-Quadruplex DNA, Inhibition of Telomerase Activity, and Induction of Tumor Cell Apoptosis
resolves10.1016/j.lfs.2018.10.024
Anticancer activity of two novel ruthenium compounds in gastric cancer cells
resolves10.1021/acs.jmedchem.0c00431
Ruthenium(II) Complex Containing a Redox-Active Semiquinonate Ligand as a Potential Chemotherapeutic Agent: From Synthesis to
<i>In Vivo</i>
Studies
resolves10.1002/anie.202006089
Necroptosis Induced by Ruthenium(II) Complexes as Dual Catalytic Inhibitors of Topoisomerase I/II
resolves10.1016/j.ccr.2014.05.018
Control and utilization of ruthenium and rhodium metal complex excited states for photoactivated cancer therapy
resolves10.1016/j.ccr.2018.03.002
Harnessing ruthenium(II) as photodynamic agents: Encouraging advances in cancer therapy
resolves10.1039/C6CC10330H
A GSH-activatable ruthenium(
<scp>ii</scp>
)-azo photosensitizer for two-photon photodynamic therapy
resolves10.1002/anie.201507800
Highly Charged Ruthenium(II) Polypyridyl Complexes as Lysosome‐Localized Photosensitizers for Two‐Photon Photodynamic Therapy
resolves10.1002/chem.201701392
Evaluation of the Medicinal Potential of Two Ruthenium(II) Polypyridine Complexes as One‐ and Two‐Photon Photodynamic Therapy Photosensitizers
resolves10.1002/anie.201204203
From One‐Photon to Two‐Photon Probes: “Caged” Compounds, Actuators, and Photoswitches
resolves10.1186/s40824-018-0140-z
Clinical development of photodynamic agents and therapeutic applications
resolves10.1016/j.oraloncology.2013.05.011
A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia
resolves10.1111/j.1365-2133.2009.09119.x
Photodynamic therapy of actinic keratoses with 8% and 16% methyl aminolaevulinate and home-based daylight exposure: a double-blinded randomized clinical trial
resolves10.1039/C7DT03613B
Controlling with light the interaction between
<i>trans</i>
-tetrapyridyl ruthenium complexes and an oligonucleotide
resolves10.1002/anie.201703890
A Red‐Light‐Activated Ruthenium‐Caged NAMPT Inhibitor Remains Phototoxic in Hypoxic Cancer Cells
resolves10.1039/C7CC01459G
Illuminating cytochrome P450 binding: Ru(
<scp>ii</scp>
)-caged inhibitors of CYP17A1
resolves10.1039/b917753a
Photoactivated chemotherapy (PACT): the potential of excited-state d-block metals in medicine
resolves10.1098/rsta.2012.0519
Photoactivatable metal complexes: from theory to applications in biotechnology and medicine
resolves10.1039/C4SC03759F
Combination of Ru(
<scp>ii</scp>
) complexes and light: new frontiers in cancer therapy
resolves10.1016/j.biomaterials.2015.04.002
Ruthenium(II) polypyridyl complexes as mitochondria-targeted two-photon photodynamic anticancer agents
resolves10.1039/C4DT01755B
Fusion of photodynamic therapy and photoactivated chemotherapy: a novel Ru(
<scp>ii</scp>
) arene complex with dual activities of photobinding and photocleavage toward DNA
resolves10.1039/C5DT02081F
Synthesis, characterization and biological evaluation of mixed-ligand ruthenium(
<scp>ii</scp>
) complexes for photodynamic therapy
resolves10.1021/jm500566f
Synthesis, Characterization, and Biological Evaluation of New Ru(II) Polypyridyl Photosensitizers for Photodynamic Therapy
resolves10.1016/S1011-1344(00)00021-X
A comparative study of the photosensitizing characteristics of some cyanine dyes
resolves10.1038/s41467-020-16993-0
Rationally designed ruthenium complexes for 1- and 2-photon photodynamic therapy
resolves10.1039/C5CC05172J
A luminescent ruthenium(
<scp>ii</scp>
) complex for light-triggered drug release and live cell imaging
resolves10.1002/anie.201309576
A Bis(dipyridophenazine)(2‐(2‐pyridyl)pyrimidine‐4‐carboxylic acid)ruthenium(II) Complex with Anticancer Action upon Photodeprotection
resolves10.1021/ja307288s
Molecular and Cellular Characterization of the Biological Effects of Ruthenium(II) Complexes Incorporating 2-Pyridyl-2-pyrimidine-4-carboxylic Acid
resolves10.1021/jacs.9b11313
A Dinuclear Ruthenium(II) Complex Excited by Near-Infrared Light through Two-Photon Absorption Induces Phototoxicity Deep within Hypoxic Regions of Melanoma Cancer Spheroids
resolves10.1039/c0dt01168a
Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(iii) complex NAMI-A by interactions with human serum albumin
resolves10.1007/s00775-009-0578-5
Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR
resolves10.1021/cr040704h
Interactions of Antitumor Metallodrugs with Serum Proteins: Advances in Characterization Using Modern Analytical Methodology
resolves10.1039/c2mt20072d
Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells
resolves10.1021/ic202029e
Pyridine Analogues of the Antimetastatic Ru(III) Complex NAMI-A Targeting Non-Covalent Interactions with Albumin
resolves10.1021/acs.jmedchem.6b00600
X-ray Structure Analysis of Indazolium<i>trans-</i>[Tetrachlorobis(1<i>H</i>-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism
resolves10.1007/s00775-010-0635-0
Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry
resolves10.1039/c0mt00101e
Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin
resolves10.1039/c3dt51763b
Kinetic and mechanistic studies on reactions of diruthenium(ii,iii) with biologically relevant reducing agents
resolves10.1021/jm0490742
Redox-Active Antineoplastic Ruthenium Complexes with Indazole: Correlation of in Vitro Potency and Reduction Potential
resolves10.1039/b511792e
Redox behavior of tumor-inhibiting ruthenium(
<scp>iii</scp>
) complexes and effects of physiological reductants on their binding to GMP
resolves10.1039/c0dt01816c
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs
resolves10.1039/C7CS00195A
The development of anticancer ruthenium(
<scp>ii</scp>
) complexes: from single molecule compounds to nanomaterials
resolves10.1038/srep43005
Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity
resolves10.1021/acschembio.9b00843
Metallointercalator [Ru(dppz)<sub>2</sub>(PIP)]<sup>2+</sup> Renders BRCA Wild-Type Triple-Negative Breast Cancer Cells Hypersensitive to PARP Inhibition
resolves10.1039/C9MT00051H
First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids <i>in vitro</i>
resolves10.1021/acsmedchemlett.9b00098
High in Vitro and in Vivo Tumor-Selective Novel Ruthenium(II) Complexes with 3-(2′-Benzimidazolyl)-7-fluoro-coumarin
resolves10.1016/j.ejmech.2019.06.061
Novel tetranuclear ruthenium(II) arene complexes showing potent cytotoxic and antimetastatic activity as well as low toxicity in vivo
resolves10.1021/acs.inorgchem.9b00853
Synthesis, Structure, Stability, and Inhibition of Tubulin Polymerization by Ru<sup>II</sup>–<i>p</i>-Cymene Complexes of Trimethoxyaniline-Based Schiff Bases
resolves10.1002/cmdc.202000096
Preclinical Anticancer Activity of an Electron‐Deficient Organoruthenium(II) Complex
resolves10.1016/j.ejmech.2020.112695
Heterofunctional ruthenium(II) carbosilane dendrons, a new class of dendritic molecules to fight against prostate cancer
The 4 references without a DOI — listed, not checked
no DOI — not checkedThe Organometallic Chemistry of the Transition Metals
no DOI — not checkedref50
no DOI — not checkedref72
no DOI — not checkedref78
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.2147/dddt.s275007"><img src="https://citestamp.com/citestamped/10.2147/dddt.s275007/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.2147/dddt.s275007)